Loading
A phase 3 trial testing Calderasib in non-small-cell lung cancer, now recruiting.
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) is a phase 3 interventional study registered as NCT07554339, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015). Planned enrolment is 310 participants (estimated). The study started in 2026-06-18 and primary completion is expected in 2032-12-15. No results have been posted on ClinicalTrials.gov.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, KRAS G12C-mutant non-small-cell lung cancer, Merck & Co. (MSD), Non-small-cell lung cancer.
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer.